(Q41728099)

English

Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.

scientific article published on 24 September 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Adrian F. Hernandez

17

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

author name string

Tariq Ahmad

1

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Philip Yin

2

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Jeffrey Saffitz

3

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Paul J Pockros

4

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Jacob Lalezari

5

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Mitchell Shiffman

6

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Bradley Freilich

7

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Joann Zamparo

8

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Kyle Brown

9

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Dessislava Dimitrova

10

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Monica Kumar

11

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Doug Manion

12

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Margo Heath-Chiozzi

13

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Robert Wolf

14

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Eric Hughes

15

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Andrew J Muir

16

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

language of work or name

0 references

publication date

24 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

62

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

409-416

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27488

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27488

21 January 2018

Current and future therapies for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27488

21 January 2018

The race for interferon-free HCV therapies: a snapshot by the spring of 2012.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27488

21 January 2018

Expediting drug development--the FDA's new "breakthrough therapy" designation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27488

21 January 2018

INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27488

21 January 2018

A Twenty-Eight-Day Mechanistic Time Course Study in the Rhesus Monkey with Hepatitis C Virus Protease Inhibitor BILN 2061

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27488

21 January 2018

Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27488

21 January 2018

The FDA critical path initiative and its influence on new drug development.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27488

21 January 2018

Identifiers

10.1002/HEP.27488

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41728099&oldid=1541896628"